PD-L1 expression heterogeneity in non-small cell lung cancer

Evaluation of small biopsies reliability

Enrico Munari, Giuseppe Zamboni, Marcella Marconi, Marco Sommaggio, Matteo Brunelli, Guido Martignoni, George J. Netto, Francesca Moretta, Maria Cristina Mingari, Matteo Salgarello, Alberto Terzi, Vincenzo Picece, Carlo Pomari, Gianluigi Lunardi, Alberto Cavazza, Giulio Rossi, Lorenzo Moretta, Giuseppe Bogina

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstrated to be highly effective in many tumor types and represents a true revolution in oncology. Recently, the anti-PD1 agent pembrolizumab was granted FDA approval for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors show PD-L1 expression in ≥ 50% of neoplastic cells and as a second line treatment for patients with NSCLC expressing PD-L1 in ≥1% of neoplastic cells, evaluated with a validated assay. For the large majority of patients such evaluation is made on small biopsies. However, small tissue samples such as core biopsies might not be representative of tumors and may show divergent results given the possible heterogeneous immunoexpression of the biomarker. We therefore sought to evaluate PD-L1 expression concordance in a cohort of 239 patients using tissue microarrays (TMA) as surrogates of biopsies stained with a validated PD-L1 immunohistochemical assay (SP263) and report the degree of discordance among tissue cores in order to understand how such heterogeneity could affect decisions regarding therapy. We observed a discordance rate of 20% and 7.9% and a Cohen's κ value of 0.53 (moderate) and 0,48 (moderate) for ≥ 1% and ≥ 50% cutoffs, respectively. Our results suggest that caution must be taken when evaluating single biopsies from patients with advanced NSCLC eligible for immunotherapy; moreover, at least 4 biopsies are necessary in order to minimize the risk of tumor misclassification.

Original languageEnglish
Pages (from-to)90123-90131
Number of pages9
JournalOncotarget
Volume8
Issue number52
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Biopsy
Immunotherapy
Neoplasms
Therapeutics
Biomarkers

Keywords

  • Immunotherapy
  • Lung cancer
  • PD-L1
  • Pembrolizumab
  • SP263

ASJC Scopus subject areas

  • Oncology

Cite this

Munari, E., Zamboni, G., Marconi, M., Sommaggio, M., Brunelli, M., Martignoni, G., ... Bogina, G. (2017). PD-L1 expression heterogeneity in non-small cell lung cancer: Evaluation of small biopsies reliability. Oncotarget, 8(52), 90123-90131. https://doi.org/10.18632/oncotarget.21485

PD-L1 expression heterogeneity in non-small cell lung cancer : Evaluation of small biopsies reliability. / Munari, Enrico; Zamboni, Giuseppe; Marconi, Marcella; Sommaggio, Marco; Brunelli, Matteo; Martignoni, Guido; Netto, George J.; Moretta, Francesca; Mingari, Maria Cristina; Salgarello, Matteo; Terzi, Alberto; Picece, Vincenzo; Pomari, Carlo; Lunardi, Gianluigi; Cavazza, Alberto; Rossi, Giulio; Moretta, Lorenzo; Bogina, Giuseppe.

In: Oncotarget, Vol. 8, No. 52, 01.01.2017, p. 90123-90131.

Research output: Contribution to journalArticle

Munari, E, Zamboni, G, Marconi, M, Sommaggio, M, Brunelli, M, Martignoni, G, Netto, GJ, Moretta, F, Mingari, MC, Salgarello, M, Terzi, A, Picece, V, Pomari, C, Lunardi, G, Cavazza, A, Rossi, G, Moretta, L & Bogina, G 2017, 'PD-L1 expression heterogeneity in non-small cell lung cancer: Evaluation of small biopsies reliability', Oncotarget, vol. 8, no. 52, pp. 90123-90131. https://doi.org/10.18632/oncotarget.21485
Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G et al. PD-L1 expression heterogeneity in non-small cell lung cancer: Evaluation of small biopsies reliability. Oncotarget. 2017 Jan 1;8(52):90123-90131. https://doi.org/10.18632/oncotarget.21485
Munari, Enrico ; Zamboni, Giuseppe ; Marconi, Marcella ; Sommaggio, Marco ; Brunelli, Matteo ; Martignoni, Guido ; Netto, George J. ; Moretta, Francesca ; Mingari, Maria Cristina ; Salgarello, Matteo ; Terzi, Alberto ; Picece, Vincenzo ; Pomari, Carlo ; Lunardi, Gianluigi ; Cavazza, Alberto ; Rossi, Giulio ; Moretta, Lorenzo ; Bogina, Giuseppe. / PD-L1 expression heterogeneity in non-small cell lung cancer : Evaluation of small biopsies reliability. In: Oncotarget. 2017 ; Vol. 8, No. 52. pp. 90123-90131.
@article{8712e8e68aae47b998dc0502cbde7619,
title = "PD-L1 expression heterogeneity in non-small cell lung cancer: Evaluation of small biopsies reliability",
abstract = "Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstrated to be highly effective in many tumor types and represents a true revolution in oncology. Recently, the anti-PD1 agent pembrolizumab was granted FDA approval for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors show PD-L1 expression in ≥ 50{\%} of neoplastic cells and as a second line treatment for patients with NSCLC expressing PD-L1 in ≥1{\%} of neoplastic cells, evaluated with a validated assay. For the large majority of patients such evaluation is made on small biopsies. However, small tissue samples such as core biopsies might not be representative of tumors and may show divergent results given the possible heterogeneous immunoexpression of the biomarker. We therefore sought to evaluate PD-L1 expression concordance in a cohort of 239 patients using tissue microarrays (TMA) as surrogates of biopsies stained with a validated PD-L1 immunohistochemical assay (SP263) and report the degree of discordance among tissue cores in order to understand how such heterogeneity could affect decisions regarding therapy. We observed a discordance rate of 20{\%} and 7.9{\%} and a Cohen's κ value of 0.53 (moderate) and 0,48 (moderate) for ≥ 1{\%} and ≥ 50{\%} cutoffs, respectively. Our results suggest that caution must be taken when evaluating single biopsies from patients with advanced NSCLC eligible for immunotherapy; moreover, at least 4 biopsies are necessary in order to minimize the risk of tumor misclassification.",
keywords = "Immunotherapy, Lung cancer, PD-L1, Pembrolizumab, SP263",
author = "Enrico Munari and Giuseppe Zamboni and Marcella Marconi and Marco Sommaggio and Matteo Brunelli and Guido Martignoni and Netto, {George J.} and Francesca Moretta and Mingari, {Maria Cristina} and Matteo Salgarello and Alberto Terzi and Vincenzo Picece and Carlo Pomari and Gianluigi Lunardi and Alberto Cavazza and Giulio Rossi and Lorenzo Moretta and Giuseppe Bogina",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.21485",
language = "English",
volume = "8",
pages = "90123--90131",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "52",

}

TY - JOUR

T1 - PD-L1 expression heterogeneity in non-small cell lung cancer

T2 - Evaluation of small biopsies reliability

AU - Munari, Enrico

AU - Zamboni, Giuseppe

AU - Marconi, Marcella

AU - Sommaggio, Marco

AU - Brunelli, Matteo

AU - Martignoni, Guido

AU - Netto, George J.

AU - Moretta, Francesca

AU - Mingari, Maria Cristina

AU - Salgarello, Matteo

AU - Terzi, Alberto

AU - Picece, Vincenzo

AU - Pomari, Carlo

AU - Lunardi, Gianluigi

AU - Cavazza, Alberto

AU - Rossi, Giulio

AU - Moretta, Lorenzo

AU - Bogina, Giuseppe

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstrated to be highly effective in many tumor types and represents a true revolution in oncology. Recently, the anti-PD1 agent pembrolizumab was granted FDA approval for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors show PD-L1 expression in ≥ 50% of neoplastic cells and as a second line treatment for patients with NSCLC expressing PD-L1 in ≥1% of neoplastic cells, evaluated with a validated assay. For the large majority of patients such evaluation is made on small biopsies. However, small tissue samples such as core biopsies might not be representative of tumors and may show divergent results given the possible heterogeneous immunoexpression of the biomarker. We therefore sought to evaluate PD-L1 expression concordance in a cohort of 239 patients using tissue microarrays (TMA) as surrogates of biopsies stained with a validated PD-L1 immunohistochemical assay (SP263) and report the degree of discordance among tissue cores in order to understand how such heterogeneity could affect decisions regarding therapy. We observed a discordance rate of 20% and 7.9% and a Cohen's κ value of 0.53 (moderate) and 0,48 (moderate) for ≥ 1% and ≥ 50% cutoffs, respectively. Our results suggest that caution must be taken when evaluating single biopsies from patients with advanced NSCLC eligible for immunotherapy; moreover, at least 4 biopsies are necessary in order to minimize the risk of tumor misclassification.

AB - Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstrated to be highly effective in many tumor types and represents a true revolution in oncology. Recently, the anti-PD1 agent pembrolizumab was granted FDA approval for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors show PD-L1 expression in ≥ 50% of neoplastic cells and as a second line treatment for patients with NSCLC expressing PD-L1 in ≥1% of neoplastic cells, evaluated with a validated assay. For the large majority of patients such evaluation is made on small biopsies. However, small tissue samples such as core biopsies might not be representative of tumors and may show divergent results given the possible heterogeneous immunoexpression of the biomarker. We therefore sought to evaluate PD-L1 expression concordance in a cohort of 239 patients using tissue microarrays (TMA) as surrogates of biopsies stained with a validated PD-L1 immunohistochemical assay (SP263) and report the degree of discordance among tissue cores in order to understand how such heterogeneity could affect decisions regarding therapy. We observed a discordance rate of 20% and 7.9% and a Cohen's κ value of 0.53 (moderate) and 0,48 (moderate) for ≥ 1% and ≥ 50% cutoffs, respectively. Our results suggest that caution must be taken when evaluating single biopsies from patients with advanced NSCLC eligible for immunotherapy; moreover, at least 4 biopsies are necessary in order to minimize the risk of tumor misclassification.

KW - Immunotherapy

KW - Lung cancer

KW - PD-L1

KW - Pembrolizumab

KW - SP263

UR - http://www.scopus.com/inward/record.url?scp=85032269559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032269559&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21485

DO - 10.18632/oncotarget.21485

M3 - Article

VL - 8

SP - 90123

EP - 90131

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 52

ER -